Acellular nerve allograft, sold under the brand name Avance, is a peripheral nerve scaffold. The most common adverse reactions include procedural pain and increased sensitivity to sensory stimuli, such as touch, temperature, and pain (hyperesthesia). Acellular nerve allograft was approved for medical use in the United States in December 2025.
Medical uses Acellular nerve allograft is indicated for the treatment of people with sensory nerve discontinuity and mixed and motor nerve discontinuity. Acellular nerve allograft is made using nerve tissue from deceased donors (cadavers) that has been specially processed to remove cells while preserving the natural structure that helps nerves regrow.
Society and culture
Legal status Acellular nerve allograft was approved for medical use in the United States in December 2025. The US Food and Drug Administration granted approval of acellular nerve allograft to Axogen.
References
Further reading
External links Clinical trial number NCT01809002 for "Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair (RECON)" at ClinicalTrials.gov Clinical trial number NCT00948025 for "A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options (CHANGE)" at ClinicalTrials.gov Clinical trial number NCT01526681 for "Registry of Avance Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction (RANGER)" at ClinicalTrials.gov